Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) and REGENXBIO (NASDAQ:RGNX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.
Valuation & Earnings
This table compares Artiva Biotherapeutics and REGENXBIO”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Artiva Biotherapeutics | $250,000.00 | 1,421.72 | -$83.86 million | ($3.30) | -2.20 |
| REGENXBIO | $170.44 million | 2.89 | -$193.88 million | ($3.79) | -1.97 |
Analyst Ratings
This is a summary of current recommendations and price targets for Artiva Biotherapeutics and REGENXBIO, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Artiva Biotherapeutics | 1 | 0 | 4 | 1 | 2.83 |
| REGENXBIO | 1 | 3 | 9 | 1 | 2.71 |
Artiva Biotherapeutics currently has a consensus target price of $39.00, indicating a potential upside of 436.45%. REGENXBIO has a consensus target price of $23.17, indicating a potential upside of 210.96%. Given Artiva Biotherapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Artiva Biotherapeutics is more favorable than REGENXBIO.
Profitability
This table compares Artiva Biotherapeutics and REGENXBIO’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Artiva Biotherapeutics | N/A | -53.86% | -48.16% |
| REGENXBIO | -112.58% | -220.07% | -46.04% |
Risk and Volatility
Artiva Biotherapeutics has a beta of 2.4, meaning that its stock price is 140% more volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.
Institutional & Insider Ownership
88.1% of REGENXBIO shares are held by institutional investors. 1.8% of Artiva Biotherapeutics shares are held by company insiders. Comparatively, 14.2% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Artiva Biotherapeutics beats REGENXBIO on 8 of the 14 factors compared between the two stocks.
About Artiva Biotherapeutics
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
About REGENXBIO
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
